The evolutionarily conserved miRNA-137 targets the neuropeptide hypocretin/orexin and modulates the wake to sleep ratio

Anja Holmabc1,2, Marie-Laure Possovreet2, Mojtaba Bandarabadi6, Kristine F. Moseholm4d6, Jessica L. Justinussen1e, Ivan Bozić6, René Lemcke6, Yoan Arribat6, Francesca Amati1, Asli Silhataroglu1f, Maxime Juventini1, Antoine Adamantidis6g, Mehdi Tafti4h, and Birgitte R. Kornum1ace,3

Edited by Joseph Takahashi, The University of Texas Southwestern Medical Center, Dallas, TX; received July 5, 2021; accepted March 2, 2022; published April 22, 2022.

Hypocretin (Hcrt), also known as orexin, neuropeptide signaling stabilizes sleep and wakefulness in all vertebrates. A lack of Hcrt causes the sleep disorder narcolepsy, and increased Hcrt signaling has been speculated to cause insomnia, but while the signaling pathways of Hcrt are relatively well-described, the intracellular mechanisms that regulate its expression remain unclear. Here, we tested the role of microRNAs (miRNAs) in regulating Hcrt expression. We found that miR-137, miR-637, and miR-654-5p target the human HCRT gene. miR-137 is evolutionarily conserved and also targets mouse Hrt as does miR-665. Inhibition of miR-137 specifically in Hcrt neurons resulted in Hcrt upregulation, longer episodes of wakefulness, and significantly longer wake bouts in the first 4 h of the active phase. IL-13 stimulation upregulated endogenous miR-137, while Hcrt mRNA decreased both in vitro and in vivo. Furthermore, knockdown of miR-137 in zebrafish substantially increased wakefulness. Finally, we show that in humans, the MIR137 locus is genetically associated with sleep duration. In conclusion, these results show that an evolutionarily conserved miR-137:Hcrt interaction is involved in sleep–wake regulation.

Sleep | Wake | miR-137 | Hypocretin | Orexin

Hypocretins (Hcrts), also known as orexins, are hypothalamic neuropeptides essential for the proper regulation of vigilance states. The hypocretin neuropeptide precursor (HCRT) and its peptide products hypocretin-1 and hypocretin-2 (HCRT-1 and HCRT-2, respectively) are expressed exclusively in the lateral hypothalamus (1, 2), and Hcrt expression shows a diurnal pattern with a peak during the active phase (3). Hcrt signaling is linked to active waking behaviors (4, 5).

Narcolepsy type 1 (NT1) patients have almost no signal from HCRT mRNA in the brain and low levels of HCRT-1 in the cerebrospinal fluid (6). Narcolepsy patients suffer from excessive daytime sleepiness and cataplexy (loss of muscle tone triggered by strong emotions), and Hcrt knockout animals also experience more sleep episodes during the active phase and cataplexy (7). Optogenetic stimulation of Hcrt neurons during sleep causes transition to wakefulness (8), and overactivity of the Hcrt was suggested as being one of the underlying causes of insomnia (9). Despite its clinical importance, the intracellular regulation of Hcrt expression is poorly understood. Some transcription factors, such as FOXA2, NR6A1, and Ebf2, can regulate HCRT gene expression, while IGFBP3 acts as a transcriptional regulator (see ref. 10 for a review).

MicroRNAs (miRNAs) are short (20 to 25 nucleotides), noncoding regulatory RNA molecules that exert their effects on target genes by complementary binding of the mRNA strand to the mRNA target sequence, predominantly in the 3′-untranslated region (UTR), leading to either mRNA degradation or translational arrest. Presently, much research is focused on the development of therapeutic miRNAs and delivery systems, and miRNA-based therapeutics are expected to be introduced into the market within the next decades. In parallel with this development, in-depth knowledge on the function of disease-relevant miRNAs is needed.

In vertebrates, more miRNAs are expressed specifically in the brain than in any other tissue (11). Previous studies identified specific miRNAs that regulate neuronal plasticity (12) and circadian rhythms (13, 14), but no specific miRNA was shown to regulate the neurotransmitters or neuropeptides involved in sleep regulation. Here, we investigate miRNAs that could target HCRT mRNA. We demonstrate that miRNA-137 (miR-137) regulates HCRT expression in vitro and in vivo and that manipulations of miR-137 levels alter the vigilance states in both mice and zebrafish. miR-137 is genetically associated with schizophrenia and involved in the etiology of neuropsychiatric disorders (12, 15–18). Here, we examine whether the MIR137 locus is also associated with a

Significance
The hypocretin (Hcrt, also known as orexin) neuropeptides regulate sleep and wake stability, and disturbances of Hcrt can lead to sleep disorders. MicroRNAs (miRNAs) are short noncoding RNAs that fine-tune protein expression levels, and miRNA-based therapeutics are emerging. We report a functional interaction between miRNA (miR-137) and Hcrt. We demonstrate that intracellular miR-137 levels in Hcrt neurons regulate Hcrt expression with downstream effects on wakefulness. Specifically, lowering of miR-137 levels increased wakefulness in mice. We further show that the miR-137:Hcrt interaction is conserved across mice and humans, that miR-137 also regulates sleep–wake balance in zebrafish, and that the MIR137 locus is genetically associated with sleep duration in humans. Together, our findings reveal an evolutionarily conserved sleep–wake regulatory role of miR-137.

Competing interest statement: B.R.K. consults for Union Chimique Belge (UCB) Pharma, Lundbeck, and Orexia Therapeutics unrelated to this work. B.R.K. is a founder of the spin-out company Ceremedy ApS. All other authors declare that they have no competing interests.

This article is a PNAS Direct Submission.

Copyright © 2022 the Author(s). Published by PNAS.
This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1To whom correspondence may be addressed. Email: anjaholm@nordvang@gmail.com.
2A.H. and M.-L.P. contributed equally to this work.
3M.T. and B.R.K. contributed equally to this work.

This article contains supporting information online at http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112225119/-/DCSupplemental.

Published April 22, 2022.
range of sleep disorders and phenotypes, and we demonstrate an association with sleep duration.

**Results**

In Silico Prediction of miRNAs That Target the HCRT Neuropeptide Precursor mRNA. We first screened for potential miRNAs that target human *HCRT* using four target prediction algorithms (MicroCosm, TargetScan, DIANA, and PITA) available from “The miRNA body-map” (19). All of these in silico algorithms predicted that hsa-miR-137, hsa-miR-637, and hsa-miR-654-5p target the 3′-UTR of *HCRT* with 7- or 8-mers (Fig. 1A and B). Several other poorly conserved miRNAs potentially target *HCRT* but were not predicted by all four algorithms (SI Appendix, Fig. S1A). Of the predicted human miRNAs, only miR-137 is conserved across species, while among the predicted murine miRNAs, miR-665 was also predicted with moderate confidence to target human *HCRT* (Fig. 1A and S1 Appendix, Fig. S1A). Fig. 1B shows thermodynamic predictions of the interaction between the miRNAs and the corresponding 3′-UTR of human *HCRT* and mouse Hcrt. It has been suggested that G:U wobble base pairing is tolerated as a match for both RNA degradation and translation repression (20). When G:U wobble interactions are included in our analysis, miR-665 interacts strongly with hypocretin in mice and humans (SI Appendix, Fig. S1B), suggesting that the miRNA:HCrt interaction is also conserved for miR-665.

To test the functional interaction of the predicted miRNAs with human *HCRT* mRNA in vitro, we wanted to use a cell line with endogenous expression of *HCRT*. We therefore quantified the endogenous expression of *HCRT* mRNA and the miRNAs in 14 human cell lines and found that SK-N-MC and SK-N-DZ neuroblastoma cell lines expressed Hcrt, miR-137, and miR-654, but not miR-637 (SI Appendix, Fig. S2). We next investigated the miRNA:Hcrt interaction in SK-N-MC and SK-N-DZ lines by transfecting them with precursor (pre) miRNAs or scrambled pre-miRNAs (scr) as controls. Quantitative real-time PCR (qRT-PCR) analysis confirmed the formation of mature miRNAs in both cell lines (Fig. 1C and SI Appendix, Fig. S3A). We then measured the *HCRT* mRNA levels in both cell lines 24 h after transfection and found that overexpression of miR-137, miR-637, and miR-654-5p suppressed *HCRT*. None of the miRNAs consistently induced expression of any of the other miRNAs tested (Fig. 1C and SI Discussion...
Appendix, Fig. S3 B–H). We confirmed the direct interaction of the miRNAs with the 3′-UTR of Hcrt using a luciferase reporter assay as well as mutating the miRNA seed sites individually (Fig. 1D). Taken together, these results show that miR-137, miR-637, and miR-654-3p regulate Hcrt expression in vitro.

Proof of Concept That miR-137 and miR-665 Can Regulate Hcrt and HCRT-1 Peptide Levels In Vivo. To test whether the miRNAs could also regulate Hcrt expression in vivo, we performed intracerebroventricular (ICV) injection of the miRNAs or anti-miRNA oligonucleotides into the brain of mouse pups directly through the skull. For this analysis, we chose the two miRNAs that showed the best predictions in mice, namely, miR-137-3p and miR-665-3p. The low myelin content of the pup brains allows the injected substance to diffuse widely and is a simple model to test whether miRNAs modify the expression of Hcrt expression in vivo (21). We first confirmed that, consistent with the findings of previous studies in rat pups (22, 23), Hcrt mRNA and peptide were expressed in the brain of postnatal day 1 (P1) to P4 mouse pups (SI Appendix, Fig. S4 A and B). We then performed ICV injection of a mixture of miR-137-3p/miR-665-3p mimics or scrambled controls into P4 mice pups. Trypan Blue was added to confirm the injection site and the widespread diffusion (SI Appendix, Fig. S4C) (21). Two rounds of injections were performed.Brains from the first round were used for mRNA and miRNA quantifications (n = 25), while brains from the second round were used for HCRT-1 peptide quantification (n = 15). Compared with controls, we found that miR-137-3p and miR-665-3p levels were significantly higher in the miR-137-3p/miR-665-3p-mimic–treated pups (P = 0.001 and 0.002, respectively; n = 16 [control] and n = 9 [miR-137-3p/miR-665-3p]; two-tailed Student’s t test, Fig. 2B). We further observed a 44% lower level of Hcrt expression after miRNA mimic injection compared with controls (P = 0.035, n = 13 [control] and n = 9 [miR-137-3p/miR-665-3p]; Fig. 2B). To test the effect of a downregulation of the miRNAs, we performed ICV injections of a mixture of anti-miR-137-3p/anti-miR-665-3p (n = 15) or scrambled controls (n = 7) into P4 mice pups. This resulted in lower miR-137-3p and miR-665-3p levels in the anti-miR-137-3p/miR-665-3p–treated pups (P < 0.0001, n = 15 [control] and 7 [anti-miR-137-3p/miR-665-3p]; two-tailed Student’s t test, Fig. 2B). We did not find any effect on Hcrt level following anti-miRNA injection; however, we measured the HCRT-1 peptide levels in the same brains and found a 32% lower and a 41% higher level in HCRT-1 peptide expression after miRNA mimic and anti-miRNA treatments, respectively (anti-miRNA vs. control: P = 0.018; n = 15 [control] and n = 7 [anti-miR-137-3p/miR-665-3p], two-tailed Student’s t test; Fig. 2B). As a control, we used the Pcdh (Perulin 4 alpha carboxylamine dehydrogenase) gene, which is colocalized with Hcrt but not targeted by these miRNAs (24), and found that its expression was not affected by the injections (Fig. 2B). These results indicate that miR-137-3p and miR-665-3p can regulate both Hcrt mRNA and HCRT-1 peptide levels in vivo.

Neuroanatomical Distribution of miR-137 and miR-665 in the Mouse Brain and Expression Level in Mouse Hypothalamus in the Rest and Active Phases. Hsa-miR-137 and mmu-miR-137 are strongly expressed in the brain of humans and mice, respectively (19, 25), whereas miR-665 is not well characterized. To assess the neuroanatomical distribution of the miRNA-targeting miRNAs, we first conducted in situ hybridization in fresh-frozen mouse brain sections, using 5′- and 3′-digoxigenin–labeled locked nucleic acid (LNA) probes targeting mmu-miR-137-3p and mmu-miR-665-3p and found that both miRNAs are widely expressed in the brain, including in the lateral hypothalamus (SI Appendix, Fig. S5), consistent with the findings of previous studies (26). We then analyzed if mmu-miR-137-3p and mmu-miR-665-3p colocalize with the Hcrt-1 peptide using immunohistochemistry combined with fluorescence in situ hybridization (Fig. 3A). Both miRs were present in all HCRT-1–positive neurons observed.

We next investigated the endogenous expression levels of miR-137-3p and miR-665-3p in the hypothalamus at different time points. We previously reported the diurnal variation of Hcrt mRNA and HCRT-1 peptide in the mouse brain (3). Using the same brain samples, we quantified miR-137-3p and miR-665-3p expression in four groups of mice, which were euthanized at different time points over 24 h, and found a clear difference in their expression over time, with the highest levels of both miRs at zeitgeber time interval 18 to 24 (ZT18–24) (miR-137-3p ZT0–6 vs. ZT18–24, P = 0.012; miR-137-3p ZT6–12 vs. ZT12–18, P = 0.016; miR-137-3p ZT12–18 vs. ZT18–24, P = 0.0002; miR-665-3p ZT0–6 vs. ZT18–24, P = 0.011; miR-665-3p ZT12–18 vs. ZT18–24, P = 0.0001; Hcrt ZT0–6 vs. ZT18–24, P = 0.0015; Hcrt ZT6–12 vs. ZT18–24, P = 0.0004; nonparametric Kruskal-Wallis test followed by Dunn’s multiple comparisons; Fig. 3B). Overall, the total level of miR-137 was much higher than miR-665 based on their relative differences (Fig. 3C). It was demonstrated before that the endogenous miR-137 level is high in the brain (27, 28). These data show that miR-137-3p and miR-665-3p are expressed in Hcrt neurons and their expression varies significantly over the course of 24 h. This is in concordance with our hypothesis that miR-137-3p and miR-665-3p are involved in the regulation of Hcrt expression in mice.

Specific Inhibition of miR-137 in Hcrt Neurons Increases Wakefulness. We demonstrated that miR-137 is highly expressed in the hypothalamus, is present in Hcrt neurons, and has the capacity to regulate Hcrt levels. Since the levels are high, we asked whether miR-137 under normal circumstances is partially blocking Hcrt expression. This means that the downregulation of miR-137 we observe at ZT12–18 could be functionally important for allowing Hcrt expression to increase to stabilize wakefulness in the same time interval. To investigate the hypothesis that miR-137 downregulation will cause an increase in Hcrt, we injected viral vectors containing a sponge sequence of these miRNAs into the lateral hypothalamus of Hcrt-Cre mice (Fig. 4A). We also included an miR-665 sponge and an unrelated miR-128 sponge as a control in the experiment. With this method, the miRs are inhibited by binding to the sponge, specifically in Hcrt neurons. Our results indicated a resulting 3.7-fold and 2.5-fold higher levels of Hcrt expression, with inhibition of miR-137 and miR-665, respectively. The upregulation following miR-137 inhibition was statistically significant (P = 0.039, one-way ANOVA; Dunnnett’s post hoc test, n = 5 for anti-miR-137, n = 6 for anti-miR-665, and n = 5 for control; Fig. 4B). We also quantified the amounts of wakefulness and non-rapid eye movement (NREM) sleep at 4-h intervals over 24 h in a subset of these mice (Fig. 4C). We found that Hcrt neuron-specific inhibition of miR-137 was associated with significantly more wakefulness than in control mice, during the first 4 h of the dark period (ZT12–16). There was 24 ± 10% more wakefulness in anti-miR-137–injected animals than in controls during this period (anti-miR-137–injected vs. control: P = 0.037; one-way ANOVA with Dunnnett’s post hoc test, n = 5 for miR-137, n = 7 for control;
Fig. 2. In vivo targeting of Hcrt by miR-137-3p and miR-665-3p. (A) Schematic representation of ICV injection in P4 mouse pups. (B) Injection of a mixture of mu-miR-137-3p/miR-665-3p mimics (*n = 9) and anti-miR-137-3p/anti-miR-665-3p (*n = 7) in P4 pups. Littermate controls were injected with a scramble (*n = 16 per group) or an antisemblar (*n = 15). RNA was isolated and analyzed by qRT-PCR. Data are presented as the magnitude of the difference compared with controls ± SEM. HCRT-1 peptide was extracted from the brains and analyzed by radioimmunoassay (RIA) (upregulation by miRNA mimic, *P < 0.01; **P < 0.004; ***P < 0.001, two-tailed Student’s t-test).

Fig. 4C). Accordingly, we found significantly less NREM sleep in anti-miR-137 animals compared with controls during the same 4 h of the dark period (Fig. 4D). There was 56 ± 22% less NREM sleep in anti-miR-137 animals than in controls (anti-miR-137–injected vs. control: *P = 0.031; one-way ANOVA with Dunnett’s post hoc test; n = 5 for anti-miR-137, n = 7 for control; Fig. 4D). No significant differences were found between anti-miR-665–injected and control mice for wakefulness or NREM sleep. These results indicate that inhibition of miR-137 consolidates wakefulness during the early hours of the dark period, which is consistent with the circadian time when endogenous Hcrt mRNA expression starts to increase (Fig. 3B).

To investigate whether the greater wakefulness in anti-miR-137-injected animals results from longer wakefulness episodes or simply from more episodes, we quantified the distribution of bout durations (Fig. 4E). We found that anti-miR-137 animals had significantly fewer short wakefulness episodes and longer wakefulness bouts compared with the control group (anti-miR-137 vs. control: *P = 0.004 for 4- to 8-s episodes, *P = 0.014 for >512-s episodes; two-way ANOVA with Dunnetts’s post hoc test). No significant differences were found in the distribution of bout durations between anti-miR-665 animals and controls. We further assessed the dynamics of delta power (0.75 to 4 Hz) during NREM sleep, as a marker of sleep intensity (29, 30), and found a tendency toward higher values (23 ± 8%) in anti-miR-137-injected animals compared to controls during the dark period (Fig. 4F, *P = 0.063; one-way ANOVA with Dunnett’s post hoc test). These results indicate that the inhibition of miR-137 in Hcrt neurons leads to increased Hcrt levels and increased wakefulness as a result of longer wake episodes.

Overexpression of miR-137 or miR-665 Cause a Downregulation of Hcrt Expression That Is Compensated over Time. We next aimed to test the effect of miR-137-3p and miR-665-3p overexpression specifically in Hcrt neurons. To this end, we designed recombinant adeno-associated virus (rAAV) vectors containing the mature miRNA sequence driven by the murine Hcrt promoter (SI Appendix, Fig. S6A) (8), delivered by stereotaxic microinjection into the lateral hypothalamus of adult mice. Three different rAAV vectors were used carrying miR-137-3p, miR-665-3p, or a nonsilencing scrambled miRNA control. Seven days following rAAV vector injections, we found a significant downregulation of Hcrt mRNA (*P = 0.036, one-way ANOVA with Dunnett’s post hoc test comparing treatment to control, n = 6 for anti-miR-137, n = 6 for anti-miR-665, and n = 5 for control; SI Appendix, Fig. S6B). It was not possible to measure the miR levels only in the Hcrt neurons, so we quantified the miRs in whole hypothalamus homogenate. Here, we could not detect an increase in miR levels (SI Appendix, Fig. S6B). This is not surprising as both miRs are expressed in many other cell types in the area, and furthermore, the Hcrt neurons are only a small fraction of all hypothalamic cell types. With time, there appeared to be a compensatory upregulation of Hcrt expression (SI Appendix, Fig. S6C). Despite this compensatory
effect, we still detected a significant 20.4% decrease in caudal HCRT-1 levels after miR-665 upregulation ($P = 0.024$, one-way ANOVA with Dunnett’s post hoc test comparing treatment to control, $n = 8$ for anti-miR-137, $n = 9$ for anti-miR-665, and $n = 8$ for control; SI Appendix, Fig. S6D). It was previously shown that HCRT protein needs to be more than $\sim 85\%$ downregulated to see functional effects (31). It is thus unlikely that the effects that we observe after upregulation of miR-137 or miR-665 cause substantial functional changes. These data demonstrate that overexpression of miR-137 and miR-665 can lead to changes in the ratio of Hcrt mRNA to peptide, but we also show that the overexpression led to a compensatory response with time.

**IL-13 Upregulates miR-137 and Downregulates Hcrt Expression.** It could be argued that massive overexpression of the miRNAs is very artificial, so to test a more physiological relevant upregulation of the miRNA, we decided to test the effect of various cytokines. Previous studies described the role of different cytokines, e.g., tumor necrosis factor alpha (TNF-α), interferon beta (IFN-β), interferon gamma (IFN-γ), and interleukin-13 (IL-13), in regulating Hcrt expression (24, 32–34).

We therefore tested whether the regulation of Hcrt expression by any of these cytokines could be due to an upregulation of miR-137. To this end, we stimulated the human cell line SK-N-DZ with TNF-α, IFN-β, IFN-γ, and IL-13 and found that among these, IL-13 showed a dose-dependent significant upregulation of miR-137 expression while also downregulating Hcrt (one-way ANOVA: $F(3, 53) = 4.822$, $P = 0.0048$; Dunnett’s post hoc test: **$P = 0.0085$ IL-13 0.01 μg/mL vs. control, **$P = 0.0075$ IL13 0.05 μg/mL vs. control; Fig. 5A). Results from the other cytokines are shown in SI Appendix, Fig. S7. IL-13 receptor expression was reported to be 17-fold higher in Hcrt neurons compared to other neurons (24), and IL-13 might therefore target Hcrt neurons more specifically than other cytokines. Thus, we tested the effects of IL-13 treatment in vivo when injected at ZT10 before the dark-to-light transition (Fig. 5B). Our data show that the expression of miR-137-3p and miR-665-3p increased at ZT18 in IL-13–injected mice ($n = 11$) compared with controls ($n = 10$ and 9, respectively. *$P = 0.0111$ and 0.0177, respectively; two-way ANOVA with Sidak post hoc comparisons of treatment vs. control groups. Fig. 5C). As hypothesized, Hcrt mRNA expression was significantly downregulated in the same brains (*$P = 0.0340$, two-
Inhibition of miR-137 in Zebrafish Reduces Sleep and Increases Locomotor Activity. miR-137 is highly conserved across species from fish to humans (35). To investigate the effects of its inhibition in zebrafish, Danio rerio, we injected an anti-miR-137 morpholino (Mo-miR-137) into zebrafish embryos and quantified their activity and sleep/wake cycle. To avoid developmental and morphological abnormalities, a low concentration of 8 ng Mo-miR-137 was injected, as suggested in previous studies (35). To assess the impact of miR-137 inhibition on the sleep/wake distribution, we continuously recorded zebrafish locomotion for 3 d, from 5 to 8 d postfertilization (dfp), as previously described (36, 37). Larvae with morphological defects were excluded in both groups (8.9 ± 1.2% Mo-miR and 1.5 ± 0.7% Mo-control) to limit a potential extraneous bias due to the morphological defect and locomotion impairment (Fig. 6D). Inhibition of miR-137 significantly increased activity during the light period compared with control fish injected with a commonly used control morpholino (Mo-miR-137 vs. Mo-control: P = 0.043 for light 5 dfp; P = 0.0013 for light 6 dfp, P < 0.001 for light 7 dfp; two-way ANOVA with Sidak post hoc test, degrees of freedom [DF] = 5, F (5,470) = 13.76; n = 48 fish per group; Fig. 6D). Accordingly, Mo-miR-137-injected fish had significantly less sleep during all three dark periods, as well as during the third light period, compared with Mo-controls (Mo-miR-137 vs. Mo-control: P < 0.001 for dark 5 to 7 dfp, P = 0.0073 for light 7 dfp; two-way ANOVA with Sidak post hoc test; DF = 5, F (5,470) = 2.79; n = 48 fish per group; Fig. 6C). These results show that miR-137 plays a role in sleep regulation also in zebrafish. There are possible target sites for miR-137 in zebrafish hCrt mRNA (SI Appendix, Fig. S8), but since we performed a global manipulation, the effect is likely mediated via many different miR-137 targets. Overall, our findings in zebrafish support what we find in mice and suggest a conserved role for miR-137 in regulating sleep and wakefulness.

The Human miR-137 Gene Is Associated with Sleep Duration. To investigate whether miR-137 is also involved in regulating human sleep, we analyzed data from a genome-wide association study (GWAS) of 19 different sleep-related phenotypes included in the UK Biobank. A strong association was seen between single-nucleotide polymorphisms (SNPs) in the MIR137 locus (chr1: 98453556 to 98515419 (GRCh37/hg19)) and sleep duration but not with any of the other phenotypes. GWASs carried out to date using sleep duration data from the UK Biobank have identified the nearby gene DPYD (38–40), which encodes dihydropyrimidine dehydrogenase, an enzyme involved in the breakdown of pyrimidines. DPYD is not yet functionally linked to sleep regulation, and our data suggest that MIR137 might instead be the functionally relevant target gene in the locus. Indeed, the lead SNP rs12567114 is located in close proximity (12,532 bp upstream) to the MIR137 gene (Fig. 7). This shows that human sleep duration is genetically associated with the MIR137 locus and suggests that individual differences in sleep duration could be partly determined by its effects on miR-137 expression.

Discussion

Here, we describe a mechanism by which miRNAs regulate expression of the wake-promoting HCRT peptides. By combining in silico prediction with in vitro and in vivo experiments,
we identified miR-137 as an evolutionarily conserved regulator of Hcrt expression. Our results suggest that miR-665 could play a similar role. We show that miR-137 and miR-665 are expressed endogenously in Hcrt neurons and that their expression in the hypothalamus varies with the time of day. Most strikingly, we show that downregulation of miR-137 in Hcrt neurons increases Hcrt mRNA levels and subsequently strengthens wakefulness at the beginning of the dark period. Using acute injections of miR-137 and miR-665 mimics and viral vector-mediated overexpression, we also show that overexpression of these miRNAs can downregulate Hcrt but with less impact. Endogenous miR-137 levels in the hypothalamus are high, suggesting that Hcrt mRNA might always be partially regulated by miR-137. The lowest levels of miR-137 are seen in the beginning of the dark period coinciding with maximal wakefulness in mice.

miR-137 is one of the most abundant and enriched miRNAs in the brain of adult mice and humans, with a high level of expression in the neocortex and hippocampus and a low level in the cerebellum and brainstem (27, 28). Embryonic development depends on the expression of at least one functional allele of MIR137, with embryonic lethality occurring in all homozygous (+/-) embryos (41). Clear developmental effects were ascribed to miR-137 (42), but the effects on Hcrt expression and wakefulness reported here cannot be explained by such processes, as our manipulations, in vitro and in vivo, were either acute or induced in fully mature adult animals. Importantly, the types of manipulations we performed only partially inhibited the miRNAs and can thus not be compared to full knockout models.

miR-137 is an evolutionarily conserved miRNA. Here, we show that the role of miR-137 in regulating the wake to sleep ratio is present in both mice and zebrafish. This could be ascribed to the interaction between miR-137 and Hcrt but could also be due to many other genes targeted by miR-137. It is well known that miRNAs regulate a large number of genes, as is also the case for miR-137 (43). PDE10A, BDNF, and CACNA1C are other known targets of miR-137 (44). The human miR-137 host gene (MIR137) has several common variants located within or near the gene on chromosome 1. Here, we used data from the UK Biobank to show that the MIR137 locus is also associated with sleep duration in healthy individuals. While we clearly demonstrate that miR-137 and its alignment with the Hcrt sequence is conserved across mice and...
Fig. 6. Knockdown of miR-137 increases locomotor activity and reduces sleep in zebrafish. (A) Morphological evaluation of zebrafish after knocking down miR-137. The developmental defect rate in 5-dpf larvae is less than 10% (Left, combined dataset from four independent experiments, Mo-miR-137: n = 223, Mo-control: n = 207 fish). Right shows representative morphological images of normal and abnormal fish (Right). (B) Time course of the locomotion activity 5 to 7 dpf (right), and the average activity per 14 h:10 h light:dark cycle (Left). Mo-miR-137 fish are significantly more active during the light phase than Mo-controls (Mo-miR-137 vs. Mo-control: P < 0.05 for light 5 dpf; P < 0.01 for light 6 dpf; P < 0.001 for light 7 dpf; F = 13.76; DF = 5; two-way ANOVA with Sidak post hoc test; **P < 0.01; ***P < 0.001; representative figure with Mo-miR-137: n = 48, Mo-control: n = 48 fish). (C) Time course of the amount of sleep 5 to 7 dpf (right), and the average amount of sleep per light/dark cycle (Left). Mo-miR-137 fish sleep significantly less during dark periods than Mo-controls (Mo-miR-137 vs. Mo-control: P < 0.001 for dark 5 to 7 dpf; P < 0.01 for light 7 dpf; F = 2.79; DF = 5; two-way ANOVA with Sidak post hoc test; representative figure with Mo-miR-137: n = 48, Mo-control: n = 48 fish).

Our study shows that noncoding RNAs regulate a neurotransmitter/peptide system involved in homeostatic regulation of the sleep-wake cycle, and our findings raise the question of whether dysregulation of miR-137 is the basis of disturbed sleep under certain circumstances.

Narcolepsy is the model disease of the hypocretin system. In NT1, patients lack hypocretin, and as a result, they suffer from excessive daytime sleepiness and cataplexy, among other sleep-related symptoms (48). The disease is likely to be caused by an autoimmune pathogenesis, even though this is not convincingly proven yet (49). The miRs we describe here are unlikely to play a major role in narcolepsy, as they most likely cannot induce such a massive lowering of HCRT-1 levels as is normally seen in NT1. Even with viral vector-mediated overexpression of the miRs, we only see up to a 20% decrease in Hcrt-1 levels. Interestingly, there are rare instances of narcolepsy with intermediate HCRT-1 levels (50). In these cases, the etiology is completely unknown, and here, one could speculate whether miR-137 is involved. miR-137 could also be involved in insomnia, where too much Hcrt signaling could play a role, or in psychiatric diseases, where sleep is often disturbed. The MIR137 locus has a strong genetic association with schizophrenia and has also been suggested to be involved in the etiology of other neuropsychiatric disorders (12, 15–18). miR-137 expression is dysregulated in schizophrenia and Rett-syndrome (51–53). Furthermore, microdeletions encompassing MIR137 are linked to autism and intellectual disability (28, 54). Patients suffering from neuropsychiatric disorders often have poor sleep quality (55, 56). The interaction reported here between miR-137, Hcrt, and sleep regulation could therefore play an important role in several neurological and neuropsychiatric diseases featuring disturbed sleep-wake patterns and could pave the way for treatments.

human, our functional zebrafish data and human genetic data offer only circumstantial evidence that there could also be a conserved functional role of the miR-137:Hcrt interaction. More research is needed before firm conclusions can be made.

Our data suggest that miR-137 binding to and inhibiting translation of Hcrt mRNA play a posttranscriptional role in Hcrt regulation. It would be interesting to know under which physiological circumstances this regulatory mechanism comes into play. Many immune mediators, such as cytokines, have known effects on sleep (45), and several studies reported a direct effect of cytokines on Hcrt neurons (24, 32–34). The mechanisms behind these effects are largely unknown. We therefore tested whether miR-137 and miR-665 could play a role in the regulation of Hcrt by cytokines. Our results support the hypothesis that IL-13 regulates the expression of Hcrt through changes in miRNA levels. Previous studies also showed that miRNAs are involved in IL-13 signaling in macrophages (46) and fibroblasts (47). We also tested TNF-α, IFN-γ, and IFN-β in vitro, but we found no clear evidence of any effects. As these cytokines have a wide range of functions in the brain, their specific effects on miRNA and Hcrt levels might be difficult to detect. Thus, it remains unclear whether the link between IL-13, miR-137, and Hcrt is unique. IL-13 could be a more specific regulator of Hcrt compared to other cytokines, as its receptor transcript is highly enriched in Hcrt neurons compared to other neurons (24).
Materials and Methods

Cell Culture Experiments. miRNA mimics designed to function as mature endogenous miRNAs were obtained from Thermo Scientific (all miRNA mimics are listed in SI Appendix) and transfected using Lipofectamine 2000 into SK-N-MC and SK-N-DZ cells. For the Luciferase reporter assay the 3’-UTR-hypocretin sequence with normal or mutated miRNA seed sites were cloned into the SICHECK-2 vector (Promega), generating Luciferase reporter constructs. Primers used for cloning and site-directed mutagenesis are can be found in Dataset S1.

Animals. C57BL/6 mice for cytokine injection (only males) and breeding were obtained from Taconic Europe and housed at Glostrup Research Institute (license #2014-15-2934-01069). Animals were maintained under standard conditions with constant room temperature (24 °C) and a 12-h light/dark cycle (lights on at 7:00 AM). Standard laboratory food (Altromin 1310) and water were provided ad libitum. P4 mouse pups bred in-house were used for all in vivo ICV injections (license #2014-15-2934-01069).

C57BL/6 mice for AAV injections were obtained from Charles River, and Hcrt-CreKI mice were bread locally. Animals were maintained under standard conditions at constant room temperature (22 °C) and a 12-h light/dark cycle (lights on at 7:00 AM). Standard laboratory food and water were provided ad libitum. AAV and electrophysiology (EEG) experiments were carried out in accordance with the BE 113/13 animal regulations and the regulations of the Swiss Federal and State of Vaud Veterinary Offices.

Viral Vector-Mediated miRNA Inhibition and Overexpression. For the development of sponge constructs for inhibiting the miRNAs, recombinant AAVs were obtained from Vector Biolabs. The human synapsin 1 gene promoter was used as a specific neuronal promoter. Complementary sequences of the miRNAs were inserted between two lox sites, followed by a GFP marker, to obtain final vectors of pAAV-hSyn-double-floxed EGFP-miR-137-3p-sp for miR-137, pAAV-hSyn-double-floxed EGFP-miR-665-3p-sp for miR-665, and pAAV-hSyn-double-floxed EGFP-miR-128sp for miR-128.

For miRNA overexpression, the following miRNA-AAV vectors were used: mmu-miR-137-3p (stock-keeping unit [SKU#: AAV-M10000163]), mmu-miR-665-3p (SKU#: AAV-M10004171), and a control-miRNA vector (mmu-miR-155 scrambled sequence). Serotypes AAV2 and AAV5 were used as inverted terminal repeat and capsid virus, and the EF1a promoter was exchanged with the mouse Hcrt promoter.

EEG/Electromyography (EMG) Recordings of Sleep States. For the anti-miRNA study, viral injections in the lateral hypothalamus (anterior-posterior [AP]: –1.4 mm; medial-lateral [ML]: ±1 mm; dorsal-ventral: –5.4 mm) and electrode implantations were performed on mice aged 10 to 12 wk. Animals were anesthetized and fixed in the stereotaxic frame for viral injections and EEG/EMG instrumentation. EEG/EMG electrodes were implanted through the skull in the frontal (AP: +1.5 mm, ML: –1.7 mm to bregma) and the parietal (1.5 mm anterior to lambda, ML: 1.7 mm to bregma) cortices of the right hemisphere and served as EEG electrodes. Two gold wires were placed in the neck muscle to serve as the EMG electrodes. Vigilance states (wake, NREM, and rapid eye movement [REM] sleep) were scored manually in 4-s epochs by visual inspection of concurrent EEG/EMG/video recordings. Power spectral density of EEG recordings was estimated using the discrete Fourier transform of 4-s epochs with a Hanning window and 0.25-Hz frequency resolution.

Inhibition of miR-137 in Zebrafish. Morpholino oligonucleotides were obtained from Gene Tools and injected into 1- to 2-cell zebrafish zygotes (Danio rerio; Oregon AB using a microinjector [Femtojet 4i, Eppendorf]). Morpholino sequences were designed according to Giacomotto et al. (35), namely, Mo-Control: 5'-CCTCCTACTCTAGTACATTAT-3' (human hemoglobin subunit beta gene) and Mo-miR-137: 5'-TCTTAAAGCTAAGCGAGGAGCC-3'. Behavioral tests were performed using the ZebraBox (Viewpoint) and its video quantification module, and sleep was defined as continuous inactivity for 60 s.

Human Genetic Data. A total of 19 sleep phenotypes and disorders GWAS summary statistics from the UK Biobank were included (Dataset S2). The genomic location of MIR137 on chromosome 1 (98.453.556 to 98.515.419 [GRCh37/hg19]) was extended to an area 1 Mbp upstream and downstream. Genes in this area were selected from the GRCh37 genome assembly and their positions marked by a blue rectangle. Any nonsignificant SNPs (P ≥ 5e-8) were plotted as gray dots, whereas significant SNPs with a P ≤ 5e-8 were plotted in dark red and labeled. Additionally, SNPs from the sleep duration GWAS (P ≤ 5e-2) were plotted in red.

Fig. 7. Genetic associations between sleep duration and the human MIR137 locus. Chromosome location of MIR137 with surrounding SNPs and genes. The plot depicts the location of MIR137 (dark-green box) on chromosome 1 (98.453.556 to 98.515.419 [GRCh37/hg19]). Genes in close genomic proximity (±1,000,000 base pairs) are marked with dark-blue boxes. The –log10-transformed values of P values for SNPs of 19 sleep phenotypes from the UK Biobank are plotted on the x axis. All genome-wide-significant SNPs with values of P ≤ 5E-8 are marked in dark red and annotated, whereas SNPs from the sleep duration GWAS with a P value between 5E-8 and 0.05 are indicated in light red. All other SNPs for different GWAS phenotypes are marked in gray. The size of the points increases with the significance of the SNP association.
Statistical Analysis. All statistical analyses were made using GraphPad Prism 8. Results were compared using Student’s t test, one-way or two-way ANOVA, or nonparametric Kruskal–Wallis test followed by multiple-comparison tests when pertinent. Statistical significance was expressed as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Data Availability. Custom MATLAB (MathWorks) scripts used to process data have been deposited in GitHub (https://github.com/Bandarabadi/SleepZebrafish). Details regarding cell culturing, miRNA and mRNA analyses from cell culture and mouse brain, fluorescence in situ hybridization and immunohistochemistry, cytokine stimulations, and surgical procedures are described in SI Appendix. Previously published data were used for this work (38, 39, 40).

ACKNOWLEDGMENTS. We are especially grateful to Thi Cam Ha Nguyen, Stine Christensen, Helle Kinggaard Liis Fischer, and Birte Kofoed for their technical assistance. We thank Professor Johan Jakobsson for the miR sponge constructs, Professor Luis De Lecea for the mmu-hypocretin promotor, and Professor Torben Ørntoft for providing the colored cancer cell lines. We acknowledge the Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of Copenhagen. The Lundbeck Foundation – LF Fellowship (A.H., K.F.M., J.L.J., and B.R.K.). We also thank The Lundbeck Foundation (R16:2013-15524 [A.H. and R77-46365 [A.S.]), Carlsberg Foundation Young Researcher Fellowship (J.L.J. and B.R.K.), The Foundation for Research in Neurology R25-A763 (A.H.), The Swiss NSF (A.A.: 310034_173126 [M.T.], 190605 [M.B.], and 18887 [F.A.]), and European Research Council (A.A.).

Author affiliations: *Department of Clinical Biochemistry, Molecular Sleep Laboratory, Rigshospitalet, 2600 Glostrup, Denmark; †Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, 2450 Copenhagen, Denmark; ‡Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Lausanne, 1015 Lausanne, Switzerland; †Department of Public Health, Section for Epidemiology, University of Copenhagen, 1356 Copenhagen, Denmark; ‡Department of Neuroscience, University of Copenhagen, 2200 Copenhagen, Denmark; ‡Department of Neurology, Center for Experimental Neurology, University of Bern, Inselspital University Hospital Bern, 3010 Bern, Switzerland; †Department of Biomedical Research, University of Bern, Inselspital University Hospital, 3010 Bern, Switzerland; ‡Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; and †Lyon Neurosciences Research Center, INSERM U, CNRS UMR 5262, University Lyon 1, 69500 Bron, France.


20. J. J. Glasscock et al., Delivery of therapeutic agents through intracebroventricular (ICV) and intravenous (IV) injection in mice. J. Vis. Exp. 56, 2948 (2011).